Genzyme gets Health Canada approval for multiple sclerosis drug Aubagio
Sanofi firm Genzyme has received approval from Health Canada for its once-daily drug Aubagio (teriflunomide) 14mg as monotherapy to treat patients with relapsing remitting multiple sclerosis (RRMS).
read all here